Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM6B | O15054 | 5/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.41 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065409 | 0.88 | GAA (0.63) | TSHRGAAHTTPDK1KMT2A | |
| SCHEMBL3062368 | 0.84 | GAA (0.64) | TSHRGAAPDK1 | |
| SCHEMBL3061621 | 0.82 | GAA (0.55) | TSHRGAACYP2C19PDK1KMT2A | |
| SCHEMBL3059962 | 0.81 | GAA (0.54) | TSHRGAAKDM4CPDK1LTB4R2 | |
| SCHEMBL3055205 | 0.81 | RAB9A (0.58) | TSHRGAAHTTPDK1KMT2A | |
| SCHEMBL3062054 | 0.81 | HTT (0.45) | TSHRGAAHTTKDM6BKDM4C | |
| SCHEMBL3060075 | 0.80 | GAA (0.53) | TSHRGAAPDK1NOS3NOS1 | |
| SCHEMBL3053488 | 0.80 | MAPK14 (0.54) | TSHRGAAPDK1KMT2ALTB4R2 | |
| SCHEMBL3054727 | 0.80 | GAA (0.53) | TSHRGAAPDK1PDK2PDK3 | |
| SCHEMBL3057449 | 0.80 | GAA (0.53) | TSHRGAAPDK1LTB4R2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| EP-2001851-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110237-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | TSHR 384/4885GAA 1212/4885HTT 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.